TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01936194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Study: NCT00410488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron - Triple Dose
Description: 0.25 mg by vein for 3 doses (days 0, 2, 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
Study: NCT03395119

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ozone
Description: After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver \>60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: 3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
Study: NCT03467152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irsenontrine
Description: Oral hypromellose capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral hypromellose capsules.
Study: NCT03872492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Assessment on mobile
Description: The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively.
Study: NCT02899169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo naturalis formula
Study: NCT03199443

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG pelvic floor
Description: EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG pelvic floor
Description: EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
Study: NCT03739229

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 LAIV
Description: 2 intranasal administrations of H7N9 live influenza vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H7N9 LAIV
Description: 2 intranasal administrations of H7N9 live influenza vaccine
Study: NCT03721029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative nerve monitoring,
Description: Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care robotic-assisted radical prostatectomy
Description: With out the usage of intraoperative nerve monitoring
Study: NCT02230488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Diabetes Case Management
Description: A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~--------------------------------------------------------------------------------
Study: NCT01811667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT02819778

Intervention type: PROCEDURE
Group type: OTHER
Intervention: usual care

Intervention type: PROCEDURE
Group type: OTHER
Intervention: S100B
Study: NCT04246931

Intervention type: OTHER
Intervention: No intervention (survey)
Description: No intervention -\> survey at 1 timepoint

Intervention type: OTHER
Intervention: No intervention (survey)
Description: No intervention -\> survey at 1 timepoint

Intervention type: OTHER
Intervention: No intervention (survey)
Description: No intervention -\> survey at 1 timepoint
Study: NCT02899169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: all-trans retinoic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Study: NCT01510288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX and ipilimumab
Description: All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
Study: NCT02226133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAAx, Inc. TigerPaw® System II
Description: Exclusion of Left Atrial Appendage.
Study: NCT04269382

Intervention type: DEVICE
Group type: OTHER
Intervention: Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements
Description: Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
Study: NCT01100957

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal intubation with a single use flexible videoscope
Description: tracheal intubation with a single use flexible videoscope
Study: NCT00410488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide chemotherapy (AI)
Description: Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
Study: NCT01100957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheal intubation with a single use flexible videoscope
Description: tracheal intubation with a single use flexible videoscope
Study: NCT02523469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Study: NCT02899169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic trioxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study: NCT04354428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
Study: NCT00410488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide chemotherapy (AI)
Description: Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinecard
Description: 750 mg/m2 as an IV bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinecard
Description: 750 mg/m2 as an IV bolus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
Study: NCT04354428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Eligible participants in a household will receive folic acid and an additional intervention drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Eligible participants in a household will receive folic acid and an additional intervention drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Description: Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
Study: NCT01639430

Intervention type: OTHER
Intervention: rectal, tympanal and temporal artery thermometry
Description: Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well.
Study: NCT03291314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
Study: NCT01564706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT03670459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercises
Description: Eye movements and head movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular habituation exercises
Description: Move from a sitting position to flat on the back

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercises
Description: Weight Shift Forward and Back
Study: NCT01380054

Intervention type: BEHAVIORAL
Intervention: Evaluation of quality of life
Description: -Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
Study: NCT03631576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123/CLL1 CAR-T Cells
Description: CD123/CLL1 CAR-T Cell Therapy
Study: NCT04301414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986218 and Degarelix
Description: BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-986218 and Degarelix
Description: BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
Study: NCT00410488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only.
Study: NCT04301414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
Study: NCT00188578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy Boost
Description: All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
Study: NCT04107038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Endotracheal Anesthesia
Description: Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitored anesthesia care
Description: Participants receive monitored anesthesia care for their procedure.
Study: NCT01950819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Induction therapy
Description: All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVR+rCNI
Description: Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPA+sCNI
Description: Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
Study: NCT02523469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Study: NCT01746433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting up
Description: The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sitting up
Description: The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient.
Study: NCT00531193

Intervention type: DRUG
Group type: OTHER
Intervention: BIIB014
Description: oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol

Intervention type: OTHER
Group type: OTHER
Intervention: [11C]SCH442416
Description: 11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
Study: NCT01111604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg IV Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Icrucumab
Description: 15 mg/kg IV Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX-6
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W
Study: NCT02606552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatrain plus aspirin
Description: Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatrain plus clopidogrel
Description: Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.

Intervention type: DEVICE
Group type: OTHER
Intervention: Amplazter Cardiac Plug (ACP)
Description: Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
Study: NCT03607721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Motion Evaluation DARI
Description: Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Motion Evaluation DARI
Description: Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
Study: NCT02078349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Description: Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
Study: NCT04115332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bio-feedback training
Description: The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
Study: NCT02324725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly